Halozyme Therapeutics Inc.
11/06/2013 | Press release | Archived content
Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
Conference Presentation Time Clarification: Halozyme will present on Wednesday, November 13th at 5:30pm ET/2:30pm MT/1:30pm PT.
SAN DIEGO, Nov. 6, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 13, 2013 at 5:30 p.m. ET/2:30 p.m. PT. Gregory I. Frost , President and Chief Executive Officer, Halozyme Therapeutics, will provide a corporate overview.
(Logo: https://http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)
The presentation will be webcast through the "Investors" section of Halozyme's corporate website at https://www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
About Halozyme Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at https://www.halozyme.com and follow us on https://www.twitter.com/HALOTherapeutic.
Investor Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 [email protected]
Media Contact: Nurha Hindi Hill + Knowlton Strategies 818-522-8411 [email protected]
SOURCE Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc. published this content on November 06, 2013, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 07, 2025 at 05:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]